Highly viscoelastic lung mucus causes many other respiratory disorders like atelectasis, bronchiectasis, bronchiolitis, bronchitis, and primary ciliary dyskinesia (PCD), giving rise to suffering and even morbidity. Under these conditions, the high viscidity of the lung secretions is often also due to high DNA concentrations, a result of a neutrophil-dominated airway inflammation. Consequently, rhDNase I may be of benefit to these patients. However, unlike the situation in CF, only a few controlled clinical trials have evaluated the efficacy of rhDNase I in these non-CF respiratory diseases. Most of the evidence of benefits are based on case reports or the experience of small groups of patients . In summary, rhDNase I has been applied with success in the treatment of atelectasis [125-131], PCD [132,133], bronchiolitis , and empyema thoracis . On the other hand, non-CF patients with bronchiectasis or bronchitis do not benefit from rhDNase I [136-139].
Was this article helpful?
If you're wanting to know more about dealing with bronchitis... Then this may be the most important letter you'll ever read! You are About To Read The Most Important Information That Is Available To You Today, You Will Achieve A Better Understanding About Bronchitis! It doesn't matter if you've never had bronchitis before or never known anyone who has, This guide will tell you everything you need to know, without spending too much brainpower!